GSK's cancer drug combination meets primary goal in late-stage trial

The results from the trial showed that Jemperli plus chemotherapy followed by Jemperli and Zejula improved progression-free survival, compared to chemotherapy alone in both the overall patient population and in a subpopulation of patients with certain types of tumours.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/gavkXcY
via